alzheimers

Researchers are finding ways to target the toxic proteins involved in neurodegenerative diseases such as Parkinson’s and Alzheimer’s that were once considered ‘undruggable.’

This sign of neurodegenerative disease often appears much earlier than other symptoms.

[Enigma Biomedical USA (Business Wire)] Enigma Biomedical USA announced the US FDA approval of TAUKLARIFY™, a radiodiagnostic agent indicated for positron emission tomography of the brain in adults with cognitive impairment who are being evaluated for Alzheimer’s disease to identify patients with tau neurofibrillary tangle pathology.

Acta Pharmacologica Sinica, Published online: 17 August 2026; doi:10.1038/s41401-026-01896-5 Oxyberberine-nanoparticle attenuates the cognitive deficits in a transgenic mouse model of Alzheimer’s disease via modulating gut microbiota through suppressing CXCL10/CXCR3 pathway

BackgroundEmerging evidence indicates that the neuroprotective effects of Astragalus polysaccharides (APS), an extract compound and bioactive constituent derived from traditional Chinese herbs, may be relevant to an effective prescription for delaying progression of Alzheimer’s disease (AD), yet the underlying mechanisms remain to be fully elucidated. This study aimed to investigate the therapeut…

Researchers have identified seven proteins in the blood that could enable better blood tests for Alzheimer's disease. A study shows that using a broader panel of markers provides a clearer picture of the disease and allows for more accurate future treatment choices.

Alzheimer's disease is an incredibly challenging condition to study, because of both its complexity, and...

Clearing amyloid plaques may break the chain reaction that fuels brain cell destruction in Alzheimer’s disease. One Alzheimer’s brain offered researchers something they almost never get to see: a natural side-by-side experiment. In some regions, years of anti-amyloid treatment had removed most of the sticky plaques associated with Alzheimer’s disease (AD). Those areas contained little [...]

Researchers at Duke Health studied more than 230 patients treated with lecanemab, a new FDA-approved therapy (known as an anti-amyloid therapy) designed to remove a protein linked to Alzheimer's disease from the brain. They found the therapy's real-world safety, treatment persistence, and effects on disease progession aligned with results from clinical trials - including the most closely watched …

Many people with less common forms of Alzheimer's disease may not qualify for newer anti-amyloid treatments designed to slow the disease, according to a study published August 5, 2026, in Neurology®, the medical journal of the American Academy of Neurology.

Sino Biological Inc. is pleased to announce the launch of its Recombinant Human p-Tau217 Protein (Cat. No. T08-50SN), a full-length, tag-free Tau reagent developed to support Alzheimer’s disease biomarker assay development, antibody evaluation, and Tau biology research.

Many people think Alzheimer’s disease begins and ends in the brain. However, scientists are discovering that changes in other parts of the body may also influence how the disease develops. A new study from Houston Methodist suggests that obesity may affect the brain through harmful fat molecules that travel from body tissues into the brain. […] The post Obesity May Send Harmful Signals to the Bra…

Surgery that aims to enhance the clearance of Alzheimer's-associated proteins from the brain has been banned in China, but only after thousands of people had the procedure

One of the hallmarks of Alzheimer's disease is the accumulation of a peptide in the brain known as amyloid beta. A new Nature Communications study published July 22 has uncovered the atomic structure of the peptide when it's damaging to the brain.

Sino Biological Inc. is pleased to announce the launch of its Recombinant Human p-Tau217 Protein (Cat. No. T08-50SN), a full-length, tag-free Tau reagent developed to support Alzheimer's disease biomarker assay development, antibody evaluation, and Tau biology research.

The misfolding of the amyloid-β protein is the strongest blood-based predictor of Alzheimer’s disease in the asymptomatic stage. It indicates the risk years before clinical diagnosis and significantly earlier than the widely used plasma biomarker P-tau 217. This is the conclusion of a study led by P...

In a new study, a team of scientists led by senior author Cyril P. Pottier, PhD, an assistant professor of neurology and of psychiatry at WashU Medicine, successfully identified three new genetic modifiers of Alzheimer’s disease development and progression in individuals who carry known autosomal dominant Alzheimer’s disease mutations. Their findings were published in Lancet Neurology.  Previous&…

New blood tests that detect early changes associated with Alzheimer's disease are making diagnosis easier and accessible to more patients, since they are less invasive than the brain scans or spinal taps typically used for a definitive diagnosis.

Researchers have identified what may be an unexpected cause of the severe sleep problems that affect many people with Alzheimer’s disease. Their study suggests that overactive immune cells, rather than protein plaques alone, may be keeping the brain awake. Sleep problems are one of the earliest and most common symptoms of Alzheimer’s disease. Many people […] The post Why People with Alzheimer’s L…